论文部分内容阅读
目的:本文重点探讨血清细胞质胸苷激酶(TK1)在甲状腺癌诊治中的临床应用价值。方法:采用CIS-1型印迹免疫-增强发光检测系统检测55例甲状腺癌患者(恶性肿瘤组)血清TK1的含量,同时检测55例甲状腺良性肿瘤患者(良性肿瘤组)中的TK1含量。结果:甲状腺癌组TK1平均浓度为(3.82±3.73pmol/L),显著高于良性肿瘤组的(2.04±1.01pmol/L),差别有统计学意义(P=0.036)。结论:血清TKl检测在甲状腺癌早期诊断、疗效监测、预后判断等方面具有一定的临床应用价值。
Objective: This article focuses on the clinical value of serum cytoplasmic thymidine kinase (TK1) in the diagnosis and treatment of thyroid cancer. METHODS: Serum TK1 levels in 55 patients with thyroid cancer (malignant tumors) were detected using the CIS-1 imprinting immuno-enhanced luminescent detection system. TK1 levels in 55 benign thyroid tumor patients (benign tumors) were also measured. Results: The average concentration of TK1 in thyroid cancer group was (3.82±3.73pmol/L), which was significantly higher than that in benign tumor group (2.04±1.01pmol/L). The difference was statistically significant (P=0.036). Conclusion: The detection of serum TK1 has certain clinical application value in the early diagnosis, curative effect monitoring and prognosis judgment of thyroid cancer.